Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

OncoSec Announces Preliminary Data from KEYNOTE-695 Study Accepted for Late-Breaking Presentation at SITC Annual Meeting

OncoSec Medical Incorporated
Posted on: 02 Nov 18
OncoSec Announces Preliminary Data from KEYNOTE-695 Study Accepted for Late-Breaking Presentation at SITC Annual Meeting

PR Newswire

SAN DIEGO and PENNINGTON, N.J., Nov. 2, 2018

SAN DIEGO and PENNINGTON, N.J., Nov. 2, 2018 /PRNewswire/ -- OncoSec Medical Incorporated (OncoSec) (NASDAQ:ONCS), a company developing intratumoral cancer immunotherapies, today announced that preliminary clinical and immunological data from its ongoing KEYNOTE-695 study, a global, multicenter, registration-directed Phase 2b trial of TAVO™ in combination with KEYTRUDA® for the treatment of metastatic melanoma, were accepted for a late-breaking Poster Presentation at the upcoming Society for Immunotherapy of Cancer (SITC) Annual Meeting to be held at the Walter E. Washington Convention Center in Washington, D.C. on November 7-11, 2018.

The details of the Poster Presentation are as follows:

Presentation Title: Initial report of intratumoral tavokinogene telseplasmid with pembrolizumab in advanced melanoma: an approach designed to convert PD-1 antibody progressors into responders.
Author: Atkinson, et. al.
Poster Number: P717
Presentation date: Friday, November 9 and Saturday, November 10, 2018

The late-breaking abstract titles can be found on the conference website here.

KEYTRUDA® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.

About OncoSec Medical Incorporated

OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target and attack cancer.  OncoSec's lead immunotherapy platform – TAVO™ (tavokinogene telseplasmid) – enables the intratumoral delivery of DNA-based interleukin-12 (IL-12), a naturally occurring protein with immune-stimulating functions. The technology, which employs electroporation, is designed to produce a controlled, localized expression of IL-12 in the tumor microenvironment, enabling the immune system to target and attack tumors throughout the body. OncoSec has built a deep and diverse clinical pipeline utilizing TAVO™ as a potential treatment for multiple cancer indications either as a monotherapy or in combination with leading checkpoint inhibitors; with the latter potentially enabling OncoSec to address a great unmet medical need in oncology: anti-PD-1 non-responders.  Results from recently completed clinical studies of TAVO™ have demonstrated a local immune response, and subsequently, a systemic effect as either a monotherapy or combination treatment approach.  In addition to TAVO™, OncoSec is identifying and developing new DNA-encoded therapeutic candidates and tumor indications for use with its ImmunoPulse® platform. For more information, please visit www.oncosec.com.

CONTACT
Investor Relations:
Stern Investor Relations
Will O'Connor
Phone: (212) 362-1200
will@sternir.com

Media Relations:
David Schemelia / Jason Rando
Tiberend Strategic Advisors, Inc. 
Phone: 212-827-0020
dschemelia@tiberend.com 
jrando@tiberend.com

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/oncosec-announces-preliminary-data-from-keynote-695-study-accepted-for-late-breaking-presentation-at-sitc-annual-meeting-300743017.html

SOURCE OncoSec Medical Incorporated

PR Newswire
www.prnewswire.com

Last updated on: 02/11/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.